| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Pedro Barbosa, Bimali Hapuarachchi, Atbin Djamshidian, Kate Strand, Andrew J Lees, Rohan de Silva, Janice L Holton, Thomas T Warne. Lower nucleus accumbens α-synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours. Brain : a journal of neurology. vol 142. issue 11. 2020-05-26. PMID:31603207. |
impulsive compulsive behaviours in parkinson's disease have been linked to increased dopaminergic release in the ventral striatum and excessive stimulation of dopamine d3 receptors. |
2020-05-26 |
2023-08-13 |
Not clear |
| Brónagh McCoy, Sara Jahfari, Gwenda Engels, Tomas Knapen, Jan Theeuwe. Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson's disease. Brain : a journal of neurology. vol 142. issue 11. 2020-05-26. PMID:31603493. |
reduced levels of dopamine in parkinson's disease contribute to changes in learning, resulting from the loss of midbrain neurons that transmit a dopaminergic teaching signal to the striatum. |
2020-05-26 |
2023-08-13 |
human |
| Edward J R Fletcher, Lawrence D F Moon, Susan Dut. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease. BMC neuroscience. vol 20. issue 1. 2020-05-26. PMID:31862005. |
parkinson's disease (pd) is characterised by dopaminergic cell loss within the substantia nigra pars compacta (snc) that leads to reduced striatal dopamine content and resulting motor deficits. |
2020-05-26 |
2023-08-13 |
mouse |
| Sameer Jauhar, Mattia Veronese, Matthew M Nour, Maria Rogdaki, Pamela Hathway, Federico E Turkheimer, James Stone, Alice Egerton, Philip McGuire, Shitij Kapur, Oliver D Howe. Determinants of treatment response in first-episode psychosis: an Molecular psychiatry. vol 24. issue 10. 2020-05-21. PMID:29679071. |
it has been proposed that dopaminergic differences underlie variation in response, with striatal dopamine synthesis capacity (dsc) elevated in responders and unaltered in non-responders. |
2020-05-21 |
2023-08-13 |
human |
| Valtteri Kaasinen, Juho Joutsa, Eero Rissanen, Laura Airas, Merja Soilu-Hänninen, Tommi Nopone. Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis. Multiple sclerosis and related disorders. vol 36. 2020-05-19. PMID:31518774. |
dopamine has a modulatory role in a number of autoimmune diseases, but there are no published cases of longitudinal dopaminergic imaging in multiple sclerosis (ms). |
2020-05-19 |
2023-08-13 |
Not clear |
| Ida Fredriksson, Malin Wirf, Pia Steenslan. The monoamine stabilizer (-)-OSU6162 prevents the alcohol deprivation effect and improves motor impulsive behavior in rats. Addiction biology. vol 24. issue 3. 2020-05-18. PMID:29480646. |
the monoamine stabilizer (-)-osu6162 (osu6162) has the ability to stabilize dopamine activity depending on the prevailing dopaminergic tone and may therefore normalize the dopaminergic transmission regulating both alcohol use disorder and impulsivity. |
2020-05-18 |
2023-08-13 |
rat |
| Esteban A Fridman, Joseph R Osborne, Paul D Mozley, Jonathan D Victor, Nicholas D Schif. Presynaptic dopamine deficit in minimally conscious state patients following traumatic brain injury. Brain : a journal of neurology. vol 142. issue 7. 2020-05-18. PMID:31505542. |
dopaminergic stimulation has been proposed as a treatment strategy for post-traumatic brain injured patients in minimally conscious state based on a clinical trial using amantadine, a weak dopamine transporter blocker. |
2020-05-18 |
2023-08-13 |
human |
| Alejandra Barroso-Hernández, Abril Ramírez-Higuera, Carolina Peña-Montes, Sergio Alberto Cortés-Ramírez, Mauricio Rodríguez-Dorantes, Óscar López-Franco, Rosa María Oliart-Ro. Beneficial effects of an algal oil rich in ω-3 polyunsaturated fatty acids on locomotor function and D Nutritional neuroscience. 2020-05-18. PMID:32420816. |
beneficial effects of an algal oil rich in ω-3 polyunsaturated fatty acids on locomotor function and d parkinson's disease (pd) is a chronic neurological disorder whose pathogenesis involves the loss of dopaminergic neurons and dopamine terminals, formation of lewy bodies, and microgliosis. |
2020-05-18 |
2023-08-13 |
Not clear |
| Akinyinka O Alabi, Abayomi M Ajayi, Benneth Ben-Azu, Osarume Omorobge, Solomon Umukor. Methyl jasmonate ameliorates rotenone-induced motor deficits in rats through its neuroprotective activity and increased expression of tyrosine hydroxylase immunopositive cells. Metabolic brain disease. vol 34. issue 6. 2020-05-14. PMID:31463866. |
decreased tyrosine hydroxylase (th) activity, due to degeneration of dopaminergic neurons contributes to the low dopamine content and the motor deficits that characterized parkinson's disease (pd). |
2020-05-14 |
2023-08-13 |
rat |
| Lilian R F Faro, Hanna Tak-Kim, Miguel Alfonso, Rafael Durá. Clothianidin, a neonicotinoid insecticide, activates α4β2, α7 and muscarinic receptors to induce in vivo dopamine release from rat striatum. Toxicology. vol 426. 2020-05-14. PMID:31479693. |
taken together, these results suggest that the stimulatory effect of clo on in vivo dopamine from rat striatum depends on the activation of α4β2 present in dopaminergic terminals and α7 nachrs subtypes expressed in glutamatergic terminals in the striatum. |
2020-05-14 |
2023-08-13 |
rat |
| Latasha L Smith, Ian T Ryde, Jessica H Hartman, Riccardo F Romersi, Zachary Markovich, Joel N Meye. Strengths and limitations of morphological and behavioral analyses in detecting dopaminergic deficiency in Caenorhabditis elegans. Neurotoxicology. vol 74. 2020-05-12. PMID:31323240. |
this study focuses on methods of measuring neurodegeneration involving the dopaminergic system and the identification of compounds with actions that disrupt dopamine function in the model organism c. elegans. |
2020-05-12 |
2023-08-13 |
caenorhabditis_elegans |
| Hidaka Haga, Kazuya Matsuo, Yasushi Yabuki, Chen Zhang, Feng Han, Kohji Fukunag. Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson's disease. Neurochemistry international. vol 129. 2020-05-11. PMID:31229554. |
administration of ep or sa4503 protected the dopaminergic neurons from mptp-induce toxicity and restored the dopamine levels in the striatum. |
2020-05-11 |
2023-08-13 |
mouse |
| Giovanni Palermo, Roberto Ceravol. Molecular Imaging of the Dopamine Transporter. Cells. vol 8. issue 8. 2020-05-11. PMID:31405186. |
dopamine transporter (dat) single-photon emission tomography (spect) with (123)ioflupane is a widely used diagnostic tool for patients with suspected parkinsonian syndromes, as it assists with differentiating between parkinson's disease (pd) or atypical parkinsonisms and conditions without a presynaptic dopaminergic deficit such as essential tremor, vascular and drug-induced parkinsonisms. |
2020-05-11 |
2023-08-13 |
Not clear |
| Sonu Singh, Akanksha Mishra, Virendra Tiwari, Shubha Shukl. Enhanced neuroinflammation and oxidative stress are associated with altered hippocampal neurogenesis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated mice. Behavioural pharmacology. vol 30. issue 8. 2020-05-11. PMID:31703031. |
dopaminergic axons directly innervate hippocampus and release dopamine in the local environment of hippocampus, and hence are directly involved in the modulation of hippocampal-dependent functions. |
2020-05-11 |
2023-08-13 |
mouse |
| Sonu Singh, Akanksha Mishra, Virendra Tiwari, Shubha Shukl. Enhanced neuroinflammation and oxidative stress are associated with altered hippocampal neurogenesis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated mice. Behavioural pharmacology. vol 30. issue 8. 2020-05-11. PMID:31703031. |
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice exhibited significantly reduced dopaminergic neurons and dopamine content that resulted in impairment of motor functions. |
2020-05-11 |
2023-08-13 |
mouse |
| Nicoleta Cristina Olarescu, Luis G Perez-Rivas, Federico Gatto, Thomas Cuny, Maria A Tichomirowa, Gianluca Tamagno, Manuel D Gahet. Aggressive and Malignant Prolactinomas. Neuroendocrinology. vol 109. issue 1. 2020-05-06. PMID:30677777. |
prolactinomas are usually benign and controllable tumors as they express abundant levels of dopamine type 2 receptor (d2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and tumor volume. |
2020-05-06 |
2023-08-13 |
Not clear |
| Renata S Auriemma, Rosa Pirchio, Dario De Alcubierre, Rosario Pivonello, Annamaria Cola. Dopamine Agonists: From the 1970s to Today. Neuroendocrinology. vol 109. issue 1. 2020-05-06. PMID:30852578. |
the discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. |
2020-05-06 |
2023-08-13 |
Not clear |
| Rosaria Formisano, Mahlet D Mersha, Jeff Caplan, Abhyudai Singh, Catharine H Rankin, Nektarios Tavernarakis, Harbinder S Dhillo. Synaptic vesicle fusion is modulated through feedback inhibition by dopamine auto-receptors. Synapse (New York, N.Y.). vol 74. issue 1. 2020-05-05. PMID:31494966. |
integrating our previous results showing the role of asic-1 in a positive feedback loop, we also put forth an updated model for synaptic vesicle fusion in which, along with dat-1 and asic-1, the dopamine auto-receptor dop-2 lies at a modulatory hub at dopaminergic synapses. |
2020-05-05 |
2023-08-13 |
caenorhabditis_elegans |
| Jill K Baird, Dennis Bourdette, Charles K Meshul, Joseph F Quin. The key role of T cells in Parkinson's disease pathogenesis and therapy. Parkinsonism & related disorders. vol 60. 2020-05-04. PMID:30404763. |
the article also discusses the important immunomodulatory effects of dopamine which may confound study of t cells in patients on dopaminergic therapies, and highlights glatiramer acetate, an fda-approved therapy for multiple sclerosis that works through modulating the t cell response, as a promising target for translation. |
2020-05-04 |
2023-08-13 |
Not clear |
| Matheus C Bianchini, Claudia Ortiz Alves Gularte, Pablo A Nogara, Bárbara N Krum, Mateus C Gayer, Jessika C Bridi, Daniel H Roos, Rafael Roehrs, Roselei Fachinetto, Simone Pinton, Daiana S Ávila, Frank Hirth, João B T Rocha, Robson L Punte. Thimerosal inhibits Drosophila melanogaster tyrosine hydroxylase (DmTyrH) leading to changes in dopamine levels and impaired motor behavior: implications for neurotoxicity. Metallomics : integrated biometal science. vol 11. issue 2. 2020-05-04. PMID:30516209. |
we focused on the dopaminergic system, and the rate-limiting enzyme tyrosine hydroxylase (dmtyrh), to test the hypothesis that thim can impair dopamine (da) homeostasis and subsequently cause dysfunction. |
2020-05-04 |
2023-08-13 |
drosophila_melanogaster |